Med24
Clinical Medicine 2. 10. 2026 • 2 min read • medical-news

Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes

The investigational triple agonist retatrutide substantially improved glycemic control and body weight in adults with obesity and type 2 diabetes, a phase III trial showed. Among 1,152 participants, average percentage of body...

Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes

A phase III trial, TRIUMPH-2, demonstrated that the investigational triple agonist retatrutide substantially improved body weight and glycemic control in adults with obesity and type 2 diabetes. At week 80, estimand data indicated average weight loss of 11.9% to 18.8% with retatrutide doses of 4 mg, 9 mg, and 12 mg, respectively, compared to 5.1% with placebo. Prior clinical trial data showed average body weight loss of 13.2% and 15.7% with high-dose semaglutide and tirzepatide, respectively. Another investigational therapy, combining eloralintide with tirzepatide, achieved a 23.3% weight loss in a type 2 diabetes population. Retatrutide’s efficacy estimand reached 20.8% weight loss. Significant reductions were observed in HbA1c, with up to 40% of participants achieving normoglycemia. Secondary endpoints showed improvements in waist circumference, triglycerides, non-HDL cholesterol, and high-sensitivity C-reactive protein. The trial, conducted across eight countries, involved 1,152 participants with a baseline BMI of 38.2 and HbA1c of 7.71%. Adverse events included gastrointestinal symptoms and hypotension. The study’s limitations included the absence of an active comparator arm and a lack of data on body composition.

Sponsored content

Original Scientific Source
medical-news
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement